Pluri has signed a $4.2M contract with the US National Institutes Of Health to advance the development of its PLX-R18 cell therapy. The therapy is a potential treatment for Hematopoietic Acute Radiation Syndrome (H-ARS), a deadly disease resulting from nuclear disasters and radiation exposure. Pluri will collaborate with the U.S. Department of Defense's Armed Forces Radiobiology Research Institute (AFRRI)/Uniformed Services University of Health Sciences (USUHS) in Maryland.